tapebrief

RVTY · Q2 2025 Earnings

Cautious

Revvity

Reported July 28, 2025

30-second summary

Revvity delivered 3% organic growth and $1.18 non-GAAP EPS in Q2, but the headline is the reset: China immunodiagnostics is now expected down high-teens for the full year on DRG reimbursement policy changes, dragging FY organic growth guidance down 1 point to 2–4% and FY adjusted EPS down to $4.85–$4.95. Management is pulling forward structural cost actions that won't be fully implemented until 2026, signaling this is not a one-quarter problem. Software was the bright spot — 32% organic growth, 115% net retention — but it cannot mask that diagnostics is now a low-single-digit grower instead of mid-single-digit.

Headline numbers

EPS

Q2 FY2025

$1.18

Revenue

Q2 FY2025

$0.72B

+4.0% YoY

Gross margin

Q2 FY2025

54.5%

Free cash flow

Q2 FY2025

$0.12B

Operating margin

Q2 FY2025

12.6%

Key financials

Q2 FY2025
MetricQ2 FY2025YoY
Revenue$0.72B+4.0%
EPS$1.18—
Gross margin54.5%—
Operating margin12.6%—
Free cash flow$0.12B—

Guidance

Prior quarter data unavailable — comparison not possible.

Segment KPIs

Q2 FY2025
SegmentQ2 FY2025YoY
Life Sciences$0.366B+5.0%
Diagnostics$0.354B+3.0%
Life Sciences Organic Growth4%—
Diagnostics Organic Growth2%—

Other KPIs

Q2 FY2025
SegmentQ2 FY2025
Organic Revenue Growth3%
Life Sciences Adjusted Operating Margin31.6%
Diagnostics Adjusted Operating Margin25.2%
Adjusted Operating Margin26.6%

Management tone

The tone shifted from "manageable headwinds with operational mitigation" to "new unforeseen headwinds requiring multi-quarter structural cost actions." Management's framing in the press release attempted to downplay China DRG impact as "only having a very modest impact on our outlook for the year," but the substance of the guide-down and the scope of cost actions extending into 2026 contradict that framing.

The China narrative deteriorated within the quarter. Management noted: "Since the start of May, we have begun experiencing increasingly larger volume-related headwinds" and "we are now expecting a fairly meaningful pullback in our immunodiagnostics business in China." This is not the language of a transient policy disruption — it is the language of a business that has been structurally repriced. The pivot to "we are also taking additional structural actions that, given their scope, will take into next year to be fully implemented" confirms that.

Confidence in diagnostics has stepped down a tier. The shift from "mid single digits" to "low single digits" for the full year is a meaningful reframing of the segment's growth profile, not a minor calibration. Coupled with the acknowledgment that "the immunodiagnostic business in China is expected to now be down high teens for the full year," diagnostics has become the drag while life sciences carries the narrative.

Software emerged as the deliberate counterweight. Management leaned into Signals software metrics — 32% organic growth, 115% net retention, record orders — more heavily than in typical quarters, signaling this is now the story they want investors to focus on. The risk: software is a smaller slice of the business and cannot offset diagnostic volume losses on the operating line.

On NIH and 2026 academic funding, management was unusually candid about the limits of visibility: "Anyone's response would be as good as mine in trying to speculate what 2026 NIH budget would look like." That refusal to forward-guide on a meaningful end market is itself a tone signal.

Recurring themes management leaned on this quarter:

China DRG policy creating unexpected volume headwinds in immunodiagnosticsStructural cost actions extending into 2026 to restore margin baselineSignals software franchise as offsetting bright spot with record ordersMacro volatility (tariffs, FX, academic funding) requiring active managementResilience and execution at high level despite headwindsShare repurchase acceleration ($450M in H1 2025) offsetting near-term EPS pressure

Risks management surfaced:

China DRG reimbursement policy expansion reducing diagnostic panel volumesContinued academic and government customer funding weaknessTariff environment volatility and evolving U.S.-Europe trade dynamicsFX headwinds creating margin pressure without corresponding profit impactGlobal birth rate declines intensifying in China, impacting newborn screening

Q&A highlights

Puneet Sudha · Lee Rink Partners

Discussion on software business sustainability, composition of growth (new contracts vs. continuing licensing), and why strong software performance isn't translating to improved gross margins despite typically higher software margins.

Management highlighted record software orders with 32% organic growth, 115% net retention, 13% APV growth, and over one-third SaaS mix. Explained margin pressure from high-margin diagnostic assay volume drops in China IDX business, not software margins themselves.

32% organic growth in signals software115% net retention rateAPV grown by 13%Over one-third of software business is now SaaS

Michael Riskin · Bank of America

On DRG policy changes in China: whether management's expectation of shift from multiplex to singleplex testing is realistic, given the policy's primary driver is cost reduction, and whether there's evidence this will be a durable change.

Management acknowledged cost is the primary driver of the DRG policy and assumed impact will continue until anniversary. Argued that from patient care perspective, singleplex testing will ultimately be required to diagnose specific autoimmune diseases, suggesting longer-term shift back to multiplex, but recognized analyst's skepticism about cost reduction goals.

Cost reduction is primary driver of DRG/minimum sufficiency policyImpact assumed to continue until policy anniversaryClinical need for singleplex testing to confirm diagnosis of specific autoimmune diseasesIDX China now less than 6% of total revenue, expected to be less than 5% in 2026

Rachel Vattenstall · JP Morgan

Tariff impact quantification: specific dollar amount of EU tariff increase from 10% to 15%, how much is embedded in guidance, and what mitigation actions are planned.

Management estimated 3-5 cents gross impact in second half from EU tariff increase to 15%, with active mitigation actions underway. Also noted tariff rates are driving re-evaluation of global manufacturing footprint and potential permanent changes to production locations.

15% EU tariff rate in framework agreement3-5 cents gross impact on EBIT in second halfActive mitigation offsetting actions in placeGlobal manufacturing footprint re-evaluation underway

Dan Brennan · TD Cohen

Breakdown of life sciences performance: reagent vs. instrument growth components, why guidance wasn't raised despite beating expectations, and trends in biopharma end market.

Management noted life sciences reagents have grown five consecutive quarters with mid-single digit pharma biotech growth showing stability. Capital equipment spend remains weak. Highlighted reagent strength despite capital equipment headwinds and confidence in continued momentum.

Five consecutive quarters of life sciences reagents growthMid-single digit pharma biotech growth in Q2Capital equipment spend continues to be pressuredNo change to guidance despite strong life sciences performance

Luke Sergots · Barclays

Life sciences operating margin dynamics: puts and takes from tariffs, FX, strong software/reagents offset by weak instruments and margin pressure; whether cost actions are incremental or pulled forward.

Management attributed margin pressure to: (1) tariff headwinds more in DX but impacting LS, (2) FX pressure on both businesses, (3) specific product mix within reagents. Cost actions are combination of pulling forward planned structural actions, re-evaluating manufacturing footprint driven by tariffs, and targeted sales/marketing reductions in China.

Tariff headwinds impact LS but greater impact in DXFX pressure on both business segmentsProduct mix within reagents created margin pressure in Q2Pulling forward some future cost actions

What to watch into next quarter

China immunodiagnostics trajectory: management guided down high-teens for FY; watch whether Q3 organic decline in this business stabilizes or accelerates beyond that, and whether management changes the "anniversary" framing for when comps normalize.

Diagnostics organic growth: segment guided to low-single-digits for FY; Q3 print needs to come in at least 2% organic to keep the full-year framing intact. Below 1% would imply a further cut.

Signals software momentum: 32% organic growth and 115% net retention are the bull case; watch whether net retention holds above 110% and whether SaaS mix continues to climb past 35%. A decel here removes the offset narrative.

2026 margin recovery setup: management telegraphed "greater than typically expected" operating margin expansion in 2026. Watch for quantification on the Q3 call — without a specific bps target, this is just words.

Manufacturing footprint actions: the EU tariff response includes "re-evaluating global manufacturing footprint." Watch for any restructuring charge or capex disclosure that quantifies the scope.

Capital equipment inflection: five quarters of reagent growth coexists with continued instrument weakness. Watch for any commentary on biopharma capex budget unlocks heading into 2026.

Sources

  1. Revvity Q2 2025 press release — https://www.sec.gov/Archives/edgar/data/31791/000003179125000022/q22025pressrelease.htm
  2. Revvity Q2 2025 earnings call transcript (management prepared remarks and Q&A)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.